Related references
Note: Only part of the references are listed.Clinical efficiency of epigenetic drugs therapy in bone malignancies
Filomena de Nigris et al.
BONE (2021)
Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma
Warren Chow et al.
CANCER (2020)
Survival and Prognosis of Chondrosarcoma Subtypes: SEER Database Analysis
Kamil M. Amer et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2020)
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
William D. Tap et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study
Lu Xie et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Faria Sultana et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma
Annemiek van Maldegem et al.
ONCOLOGIST (2019)
IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract
Matthias Tallegas et al.
HUMAN PATHOLOGY (2019)
Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA
Yuan Huang et al.
CELL CYCLE (2019)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
Phase 2 Study of Dasatinib in Patients With Alveolar Soft Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid Sarcoma, or Solitary Fibrous Tumor
Scott M. Schuetze et al.
CANCER (2017)
We Can Study Ultrarare Tumors Effectively in This Day and Age, It Just Takes a Cooperative Approach: The Role of Dasatinib in Assorted Indolent Sarcomas
Victor M. Villalobos et al.
CANCER (2017)
Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines
Eva Bernhart et al.
ONCOTARGET (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
Scott M. Schuetze et al.
CANCER (2016)
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment
Frank M. Speetjens et al.
CURRENT OPINION IN ONCOLOGY (2016)
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
Marie Kostine et al.
MODERN PATHOLOGY (2016)
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
Armin Rashidi et al.
FUTURE ONCOLOGY (2015)
Sarcoma Classification: An Update Based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone
Leona A. Doyle
CANCER (2014)
Outcome of Advanced, Unresectable Conventional Central Chondrosarcoma
Annemiek M. van Maldegem et al.
CANCER (2014)
Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
Veronica T. Campbell et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Frank G. Schaap et al.
ADVANCES IN ANATOMIC PATHOLOGY (2013)
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study
A. Italiano et al.
ANNALS OF ONCOLOGY (2013)
Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy
Yi-Xiang Zhang et al.
CLINICAL CANCER RESEARCH (2013)
Loss of RUNX3 expression may contribute to poor prognosis in patients with chondrosarcoma
Zhe Jin et al.
JOURNAL OF MOLECULAR HISTOLOGY (2013)
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K. Schwartz et al.
LANCET ONCOLOGY (2013)
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas
Rinat Bernstein-Molho et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma
Danielle Meijer et al.
GENES CHROMOSOMES & CANCER (2012)
Clinical outcome of central conventional chondrosarcoma
Andrea Angelini et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells
Catherine Bui et al.
FASEB JOURNAL (2010)
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations
Stefan Gross et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Phase I Trial of Pazopanib in Patients with Advanced Cancer
Herbert I. Hurwitz et al.
CLINICAL CANCER RESEARCH (2009)
Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database
Angela Ylenia Giuffrida et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas
Thomas J. Grifone et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2008)
The clinical approach towards chondrosarcoma
Hans Gelderblom et al.
ONCOLOGIST (2008)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo
Frank M. Klenke et al.
BMC CANCER (2007)
The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells
Riku Sakimura et al.
CLINICAL CANCER RESEARCH (2007)
Targeting the Hedgehog pathway in cancer
Lee L. Rubin et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interieukin-1β
T Kalinski et al.
CANCER (2006)
Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation
TD Tiet et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Estrogen signaling is active in cartilaginous tumors:: Implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma
AM Cleton-Jansen et al.
CLINICAL CANCER RESEARCH (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
Doxorubicin and cisplatin chemotherapy in high-grade spindle cell sarcomas of the bone, other than osteosarcoma or malignant fibrous histiocytoma: a European Osteosarcoma Intergroup Study
MA Nooij et al.
EUROPEAN JOURNAL OF CANCER (2005)
Dedifferentiated chondrosarcoma: The role of chemotherapy with updated outcomes
ID Dickey et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2004)
Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth
T Furumatsu et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Share Paper
